MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-01-2026
China Pharma Holdings Interest Expense 2011-2026 | CPHI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.3 K | 27.4 K | 30.6 K | 435 K | 542 K | 294 K | 322 K | 451 K | 539 K | 850 K | -1.17 M | 786 K | -349 K | -308 K | -255 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 850 K | -1.17 M | 148 K |
Quarterly Interest Expense China Pharma Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.8 K | 6.78 K | 6.79 K | - | 6.84 K | 6.85 K | 6.86 K | - | 6.94 K | 138 K | 79.4 K | - | 104 K | 110 K | 124 K | - | 64.9 K | 72.4 K | 71.3 K | - | 61.1 K | 63.1 K | 62 K | - | 67.6 K | 97.3 K | 86.8 K | - | 102 K | 131 K | 129 K | - | 131 K | 142 K | 139 K | - | 214 K | 244 K | -242 K | - | 279 K | 322 K | 314 K | - | -325 K | -113 K | -56.4 K | - | -89.2 K | -92 K | 82.4 K | - | -79.5 K | -78.5 K | -77.5 K | - | -62.4 K | -61.2 K | -61.2 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 322 K | -325 K | 47.5 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
500 K | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
-28 M | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
47 K | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
152 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-539 K | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
87.9 M | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
20 K | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
764 K | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
Solid Biosciences
SLDB
|
824 K | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
862 K | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
573 M | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
-29.5 K | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
-144 K | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
80.2 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-623 K | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
300 K | $ 2.07 | 0.98 % | $ 23.9 M | USA |